All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the EHA 2022 Congress, the AML Hub spoke with Brian Huntly, University of Cambridge, Cambridge, UK. We asked, What is the clinical significance of co-mutational patterns in acute myeloid leukemia (AML)?
What is the clinical significance of co-mutational patterns in AML
Huntly begins by giving a background on AML-related mutations and their effect on prognosis. Huntly discusses FLT3 mutations, and also his recent study, highlighting survival and risk outcomes. Finally, Huntly describes the individual scoring system that his research group is developing, and how it can be utilized.
What results are needed prior to therapy initiation in newly diagnosed AML?
Finally, the committee discusses the need for measurable residual disease (MRD) testing prior to initiation of therapy, highlighting recent data and the impact on...
Visual abstract | QuANTUM-First trial of quizartinib with standard chemotherapy and as continuation therapy in newly diagnosed FLT3-ITD+ AML
The AML Hub is happy to present a Visual Abstract summarizing key data from the phase III QuANTUM-First...
Subscribe to get the best content related to AML delivered to your inbox